- - In August 2023, Gilead Sciences and Tentarix Biotherapeutics entered into three multi-yr collaborations to leverage Tentarix's Tentacles platform for the invention and development of modern, multi-functional protein-based mostly therapies for cancer and inflammatory diseases.